Geovax Labs Inc

Company Profile

• Business description

  Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company’s key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

• Contact

  1900 Lake Park Drive
  Suite 380
  SmyrnaGA30080
  USA

  T: +1 678 384-7220

  E: [email protected]

  https://www.geovax.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  17